[D-Asp1]-Amyloid- Beta-Protein (1-42)

[D-Asp1]-Amyloid- Beta-Protein (1-42) is a synthetic research peptide in the amyloid-beta family. The listed sequence/design is D-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-I le-Ala. Amyloid-beta peptides are widely used to study aggregation, oligomerization, fibril formation, sequence-dependent conformational behavior, and analytical detection relevant to Alzheimer disease research. D-aspartate-containing Aβ analogs are useful for investigating age-related racemization/isomerization and its influence on aggregation.

• receptor or binding assays
• competition experiments
• enzymatic-processing studies
• antibody or antigen controls
• analytical method development
• LC-MS/HPLC reference work
• comparative structure-activity experiments

Because this product may be a fragment, substituted analog, stereochemical variant, or terminally modified form, its activity should not be assumed to be identical to the native parent peptide. Peptide solubility, aggregation, adsorption to surfaces, and stability can vary with sequence, concentration, pH, ionic strength, and terminal modifications, so assay-specific reconstitution and storage conditions should be validated experimentally.

1. Racemization of Asp23 affects aggregation of Alzheimer amyloid beta protein (PMID 8144598).
2. Racemization and neuropathogenesis of Alzheimer's disease (PMID 7761990).